|
All-cause mortality
|
Grade I
|
Grade II
|
Overall
|
| Main results |
1.06 (0.87–1.28) |
1.04 (0.82–1.31) |
1.03 (0.90–1.19) |
| Adjusted for ischemic heart disease at baseline |
1.05 (0.64–1.72) |
0.79 (0.42–1.47) |
0.96 (0.66–1.39) |
| Adjusted for socioeconomic status at baseline |
1.05 (0.87–1.27) |
1.05 (0.83–1.33) |
1.03 (0.90–1.19) |
| Individuals with no known comorbidities |
1.08 (0.87–1.34) |
1.19 (0.92–1.54) |
1.13 (0.96–1.32) |
| Stratified by gender |
|
|
|
| Women |
0.97 (0.78–1.21) |
1.02 (0.79–1.31) |
0.99 (0.85–1.16) |
| Men |
1.42 (0.97–2.07) |
1.17 (0.61–2.24) |
1.24 (0.89–1.71) |
| Time to first prescription |
|
|
|
| 3 months |
0.96 (0.76–1.20) |
0.99 (0.78–1.26) |
0.96 (0.82–1.13) |
| 9 months |
1.01 (0.84–1.22) |
1.08 (0.86–1.36) |
1.02 (0.90-1-17) |
| 12 months |
1.03 (0.87–1.23) |
1.10 (0.88–1.38) |
1.04 (0.91–1.18) |
| Stratified by follow-up time |
|
|
|
| 3 months |
1.06 (0.87–1.28) |
1.03 (0.82–1.31) |
1.03 (0.90–1.19) |
| 6 months |
1.06 (0.87–1.28) |
1.03 (0.82–1.31) |
1.03 (0.90-1-19) |
| Using only patients with diagnoses confirmed in a second thyroid function test |
- |
- |
0.90 (0.66–1.22) |
|
MI
|
Grade I
|
Grade II
|
Overall
|
| Main results |
1.66 (0.70–3.95) |
1.45 (0.49–4.31) |
1.42 (0.76–2.68) |
| Adjusted for ischemic heart disease at baseline |
0.86 (0.40–1.87) |
0.81 (0.36–1.84) |
0.89 (0.53–1.51) |
| Adjusted for socioeconomic status at baseline |
0.94 (0.62–1.43) |
1.21 (0.77–1.90) |
1.08 (0.81–1.44) |
| Individuals with no known comorbidities |
0.93 (0.57–1.51) |
1.07 (0.66–1.73) |
1.09 (0.79–1.51) |
| Stratified by gender |
|
|
|
| Women |
0.84 (0.50–1.41) |
1.05 (0.63–1.78) |
0.98 (0.70–1.38) |
| Men |
1.21 (0.58–2.51) |
1.66 (0.70–3.92) |
1.41 (0.83–2.40) |
| Time to first prescription |
|
|
|
| 3 months |
1.70 (0.71–4.05) |
2.40 (0.78–7.40) |
1.68 (0.89–3.16) |
| 9 months |
1.55 (0.69–3.46) |
1.44 (0.49–4.29) |
1.36 (0.74–2.51) |
| 12 months |
1.34 (0.60–2.99) |
1.44 (0.49–4.29) |
1.27 (0.69–2.34) |
| Stratified by follow-up time |
|
|
|
| 3 months |
1.65 (0.69–3.95) |
1.45 (0.49–4.32) |
1.42 (0.76–2.68) |
| 6 months |
1.66 (0.69–3.95) |
1.45 (0.49–4.31) |
1.42 (0.76–2.68) |
| Using only patients with diagnoses confirmed in a second thyroid function test |
- |
- |
0.72 (0.39–1.34) |
|
CV Death
|
Grade I
|
Grade II
|
Overall
|
| Main results |
1.15 (0.88–1.51) |
0.94 (0.66–1.34) |
1.02 (0.83–1.25) |
| Adjusted for ischemic heart disease at baseline |
1.09 (0.59–2.03) |
1.05 (0.51–2.14) |
1.15 (0.74–1.78) |
| Adjusted for socioeconomic status at baseline |
1.14 (0.87–1.49) |
0.93 (0.65–1.33) |
1.01 (0.83–1.24) |
| Individuals with no known comorbidities |
1.20 (0.88–1.62) |
1.03 (0.70–1.51) |
1.11 (0.88–1.39) |
| Stratified by gender |
|
|
|
| Women |
1.02 (0.74–1.40) |
0.97 (0.67–1.41) |
0.96 (0.77–1.21) |
| Men |
1.69 (1.02–2.80)* |
0.78 (0.26–2.27) |
1.32 (0.83–2.08) |
| Time to first prescription |
|
|
|
| 3 months |
1.10 (0.80–1.49) |
0.82 (0.56–1.19) |
0.93 (0.74–1.17) |
| 9 months |
1.06 (0.82–1.38) |
1.00 (0.71–1.40) |
0.99 (0.82–1.21) |
| 12 months |
1.08 (0.84–1.38) |
1.08 (0.77–1.51) |
1.03 (0.85–1.24) |
| Stratified by follow-up time |
|
|
|
| 3 months |
1.15 (0.88–1.51) |
0.94 (0.66–1.34) |
1.02 (0.83–1.25) |
| 6 months |
1.15 (0.88–1.51) |
0.94 (0.66–1.34) |
1.02 (0.83–1.25) |
| Using only patients with diagnoses confirmed in a second thyroid function test |
- |
- |
0.89 (0.58–1.38) |
